{ "slug": "mots-c-mitochondrial", "authoring_model": "Sol 6.1", "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)", "review_date": "2026-10-14", "canonical_path": "hsef_v53_final_nine_2026-10-12\\mots-c-mitochondrial\\mots-c-mitochondrial.review.md", "level_before": "Γ", "level_after": "Γ", "descriptor_after": "Mechanistically plausible, partial system support", "confidence_before": "Moderate", "confidence_after": "Moderate", "causal_role_before": "reinforcing / stabilizing factor", "causal_role_after": "reinforcing / stabilizing factor", "msd_changed": false, "pmids_checked": 67, "pmids_failed": 0, "retractions_or_eoc": 0, "claims_spot_checked": 13, "corrections_applied": 4, "counts_by_severity": { "Critical": 0, "Major": 0, "Minor": 3, "Editorial": 1 }, "validator": { "tool": "framework/hsef-hypothesis-review-v5/tools/validate_review.py", "result": "FAIL", "fail_checks": [ "v5.lay_summary" ], "passes": 33, "pre_edit_result_identical": true, "note": "The only failure is the v5.4 lay_summary requirement, which post-dates this v5.3 review; the identical failure is produced by the pre-edit file, so it is not a regression." }, "findings": [ { "id": "F1", "severity": "Minor", "type": "rendering_defect_numeric", "location": [ "Evidence and causal interpretation", "Consensus and original-source reconciliation", "evidence cards [9] [16] [18] [29] [32] [34] [53] [57] [62]", "PROPOSED DECISIVE EXPERIMENTS" ], "original": "intermittent15mg/kg dosing3times weekly beginning around23.5months; events in94hemodialysis patients; metformin over24weeks; only2of6soleus; peakVO2 in20active volunteers; MOTS-c in19active men; remodeling over12weeks; adultT2D; preserving12S-rRNA; little12S-rRNA; proposed16-amino-acid; mitochondrial12S-rRNA", "corrected": "the same statements with the spaces around numerals restored", "evidence": "Known builder defect. Values confirmed correct: PMID 33473109 reports late-life (23.5 mo) initiated intermittent treatment 3x/week; PMID 39111290 studies 94 haemodialysis patients.", "level_impact": "none" }, { "id": "F2", "severity": "Minor", "type": "rendering_defect", "location": [ "Research timeline (review)", "RESEARCH_TIMELINE.md", "research-timeline.json" ], "original": "**2015 — 2015:12S-rRNA-region peptide candidate ...** (all ten milestone headings print the year twice and run it into the text)", "corrected": "**2015 — 12S-rRNA-region peptide candidate ...**", "evidence": "Sibling reviews in this corpus print the single form '**YYYY — Text**'.", "level_impact": "none" }, { "id": "F3", "severity": "Editorial", "type": "rendering_defect", "location": [ "throughout review", "score card", "CONSENSUS_CROSSCHECK.md", "video-insert.md" ], "original": "The2015original; The2026human-MSC; Its20provider-readpapers; count once.64reports are not64studies or64independent causal lines; universal cap3; adaptation of06; Step5; rho0oractinonin; humanMSCpretreatment; worseMSCrepair; inhibitor/cellularASO; rRNA/linkedmtDNA; Original Results0–1 (and 32 further instances)", "corrected": "the same tokens with word boundaries restored", "evidence": "Same rendering defect class; no factual content changed.", "level_impact": "none" }, { "id": "F4", "severity": "Minor", "type": "confidence_rationale_from_access_depth", "location": [ "scorecard final_score.confidence_rationale" ], "original": "64 primary reports with 7 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "corrected": "Moderate reflects evidence density and reproducibility, not the reviewer's access depth and not any belief about correctness: the rodent pharmacology replicates across backgrounds and two species, but much of the programme shares peptide reagents, antibodies and paradigms across closely connected laboratories, native-peptide immunoassay specificity is unresolved, and no human administration study exists. High was considered and declined on that reagent and laboratory concentration; Low was declined because independent groups reproduce the exposure-response measurements.", "evidence": "hsef-framework.md ties the confidence band to evidence density and reproducibility and does not list the reviewer's access depth, so 'incomplete access' was not a legitimate determinant. The band itself was re-derived and retained.", "level_impact": "none; confidence band unchanged" } ], "rejected_findings": [ { "item": "headline letter Γ and aggregation", "reason": "Primary-subclaim rule pre-registered with SC3 named; all three rules genuinely return Γ (weakest-link takes the lowest of Γ/Ε/Γ; scope-matched takes SC3, the only subclaim at the registered human-administration scope). The Ε on SC2 is scope-restricted and correctly does not set the headline." }, { "item": "declared SC2 phenotype adaptation of rubric 06", "reason": "Stated in four places, archived criterion quoted verbatim, natural-aging branch held at Γ by the rubric's own single-species/single-strain hard rule. PMID 33473109's late-life physical-capacity result would arguably satisfy the unadapted healthspan criterion, making the review conservative rather than permissive." }, { "item": "causal role reinforcing / stabilizing factor (step 5)", "reason": "An adversarial case for epiphenomenon exists at the registered human scope, but the review's reasoning from bidirectional rodent pharmacologic effects is written out and defensible; the label modifies no letter." }, { "item": "momentum 'Mechanistic only'", "reason": "Required artifact present and names PMID 39559755, 41520850 and 42324588. Not the 'Decisive work underway' boilerplate." }, { "item": "errata on PMID 34320351 and 41680431 absent from reference lines", "reason": "Both corrections (34525370, 42716952) are recorded in the Access/status line of evidence cards [9] and [55], which is where this package records linked notices." }, { "item": "PMID 36490309 trailing empty author entry", "reason": "Likely a dropped collective author, but not in first position, so the builder defect does not apply and the reference renders correctly." }, { "item": "PMID 42611943 versus preprint 39553971", "reason": "Different title, journal, year and DOI; the independence section already states the preprint and the published report count once." }, { "item": "PMID 38141139 year 2025", "reason": "Print issue is Cardiovasc Drugs Ther 39(3), i.e. 2025; the 2023 e-pub year is the earlier date, so the printed year is correct." }, { "item": "partial-body claims absent from abstracts", "reason": "Clamp/dual-background/cytoplasmic-translation (25738459), predicted 12S-rRNA structure (33468709), SPR and ASO controls and the K14Q atrophy result (39559755), and the numeric disagreement (41551324) are all absent from the PubMed abstracts, but all four records are declared full_text_partial with specific body paragraphs listed. Recorded as a residual limitation, not an error." }, { "item": "inline citation form '(PMID39559755)'", "reason": "House style used throughout the corpus; garbles no value." }, { "item": "renderer bug: 'Best-supported rival' printing the nominal model", "reason": "Absent. The score card marks the rank-1 model is_nominal=false and the nominal model at its own lower rank; the AT A GLANCE prose names the rank-1 rival." }, { "item": "false-approval boilerplate and foreign-provenance clauses", "reason": "Absent. This case is not one of the 9 October revised editions, carries no 'earlier adversarial approval' sentence, and its Selection and methods provenance statements apply to this case. REVIEWER NOTES and the Consensus section do not contradict each other." }, { "item": "confidence band Moderate -> High", "reason": "Re-derived against the framework's band texts and retained at Moderate; see the finding above for the specific heterogeneity and independence limits that keep it out of the High band." } ], "residual_limitations": [ "Four load-bearing claims rest on partial-body passages not independently re-retrieved in this pass; they were checked for internal consistency and for absence of abstract-level contradiction only.", "The claim that PMID 41551324's abstract, body and table numeric summaries disagree could not be corroborated: the abstract's own counts are mutually consistent (the 10-person surgical follow-up is a subset of the 32 obese participants), so any disagreement is between body and table.", "The post-surgical statement that 'selected metabolic indices improve' is body-sourced; the abstract supports only the BMI improvement with unchanged circulating peptide." ], "package_level_strings_for_lead_to_propagate": [ { "file_hint": "READER.html / OVERVIEW.md", "old": "intermittent15mg/kg dosing3times weekly beginning around23.5months", "new": "intermittent 15 mg/kg dosing 3 times weekly beginning around 23.5 months" }, { "file_hint": "READER.html / OVERVIEW.md", "old": "events in94hemodialysis patients", "new": "events in 94 hemodialysis patients" }, { "file_hint": "READER.html / OVERVIEW.md", "old": "metformin over24weeks", "new": "metformin over 24 weeks" }, { "file_hint": "READER.html / OVERVIEW.md", "old": "only2of6soleus", "new": "only 2 of 6 soleus" }, { "file_hint": "READER.html / OVERVIEW.md", "old": "peakVO2 in20active volunteers", "new": "peak VO2 in 20 active volunteers" }, { "file_hint": "READER.html / OVERVIEW.md", "old": "MOTS-c in19active men", "new": "MOTS-c in 19 active men" }, { "file_hint": "READER.html / OVERVIEW.md", "old": "remodeling over12weeks", "new": "remodeling over 12 weeks" }, { "file_hint": "READER.html / OVERVIEW.md", "old": "The2015original", "new": "The 2015 original" }, { "file_hint": "READER.html / OVERVIEW.md", "old": "Its20provider-readpapers and matrix cells are not64examined primary reports", "new": "Its 20 provider-read papers and matrix cells are not 64 examined primary reports" }, { "file_hint": "READER.html / OVERVIEW.md", "old": "count once.64reports are not64studies or64independent causal lines.", "new": "count once. 64 reports are not 64 studies or 64 independent causal lines." }, { "file_hint": "READER.html / OVERVIEW.md", "old": "**YYYY — YYYY:Text** (duplicated year prefix in all ten timeline milestones)", "new": "**YYYY — Text**" } ], "approval": "Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.", "confidence_band_rederived": "Moderate retained; rationale rescoped off access depth", "lead_policy_applied": { "confidence_two_step_test": "Lead policy, round 2: (1) strike access depth as a confidence determinant everywhere; (2) re-derive the band from what remains, raising it only if access depth was the sole thing holding it down and the evidence meets the High text. Applied to this case; see the confidence finding for the outcome.", "momentum_decisive_work": "Lead policy, round 2: 'Decisive work underway' requires work actually being run that could cross the next threshold; a completed publication or trial never satisfies it, even when the artifact names a real study.", "false_approval_boilerplate": "Lead policy, round 2: the 2026-10-09 splice inserted 'The earlier adversarial approval refers to its original edition' unconditionally. Verify against prepublication-enrichment-2026-10-05/ADVERSARIAL_REVIEW.md before changing; rescope only where no earlier approval exists.", "renderer_best_supported_rival": "Lead policy, round 2: check the score card's is_nominal / rank_in_tournament fields; fix the prose, not the data, if the nominal is printed as the rival." } }